PA-SES
24.9.2020 08:52:58 CEST | Business Wire | Press release
SES Government Solutions (SES GS), a fully-owned affiliate of SES, and Isotropic Systems, a leading developer of transformational broadband terminal technologies, today announced a two-phased antenna evaluation contract with the U.S. Air Force Research Laboratory, working in close collaboration with the U.S. Army Research Engineering Team, for tests of Isotropic Systems’ multi-beam terminal over SES’s O3b Medium Earth Orbit (MEO) constellation to ultimately unleash next-gen connectivity across the battlefield.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200923006010/en/
It is the first customer contract between Isotropic Systems and SES Government Solutions and follows on from the significant developmental partnership currently ongoing between the two companies to produce scalable, cost-effective terminals capable of providing government, military, and commercial access to the existing O3b constellation and the groundbreaking O3b mPOWER system set to launch late next year.
The U.S. Air Force and Army, through the innovative Defense Experimentation Using Commercial Space Internet (DEUCSI) program, will review a prototype of Isotropic Systems’ optical beamforming antenna and its ability to connect simultaneously with two satellite constellations at GEO and MEO. The unique multi-beam capability will enable the armed forces to deliver data at the tactical edge by leveraging capacity from multiple commercial satellites and a military satellite over a single antenna platform.
First phase over-the-air (OTA) is scheduled to be completed by early fall, followed by the phase two in early 2021 where the Isotropic Systems optical lens technology will be utilized to demonstrate a two full performance beam connection. One beam will link with an SES geostationary (GEO) satellite, while another full performance optical beam will establish a simultaneous connection with SES’s O3b MEO satellite constellation.
The biggest user of satellite capacity in the world, the U.S. Department of Defense, is exploring new ways to more effectively and efficiently utilize both existing and new capacity coming online in GEO, MEO and LEO orbits. Isotropic Systems’ optical multi-beam terminals bring key advantages to government markets, including the flexibility to meet performance, cost, and power consumption requirements specific to defense.
"As we get ready for the launch of our O3b mPOWER MEO constellation and SES-17 GEO satellite late next year, it is vital that we work with the U.S. Government to better understand their requirements, and to partner with companies like Isotropic Systems to help us meet those needs," said Pete Hoene, President and CEO of SES Government Solutions. "The Isotropic antenna will deliver high throughput, at low latency over a MEO constellation with simultaneous resilient GEO capacity. This will be a game-changer for the U.S. Army. These collaborative trials with the U.S. Army Research Engineering Team and the Air Force bring commercial ingenuity to the men and women in uniform and the U.S. Government as a whole."
“Isotropic Systems’ collaborative tests with SES Government Solutions in support of the U.S. military is an important milestone on our roadmap leading to a multi-beam, multi-frequency terminal that allows the government and armed forces to utilize every bit of capacity in the sky,” said Scott Sprague, Chief Commercial Officer of Isotropic Systems. “That is the ultimate goal for the defense market, which is currently grappling with disparate networks to deliver connectivity to the battlespace.”
Follow us on:
Social Media
Blog
Media Library
About SES Government Solutions
SES Government Solutions (SES GS) is a wholly-owned subsidiary of global satellite operator SES. SES GS operates under a proxy board allowing them to provide services through contracts with the U.S. Government, including classified work. SES GS is exclusively focused on meeting the satellite communications needs of the U.S. Government. Leveraging more than four decades of experience in the government SATCOM market, SES Government Solutions offers robust and secure end-to-end satellite communications solutions. Further information can be found at www.ses-gs.com
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,300 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
About Isotropic Systems
Isotropic Systems is developing the world’s first multi-service, high-bandwidth, low power, fully integrated high throughput terminals designed to support the satellite industry to 'reach beyond' traditional markets and acquire new customers with a full suite of high throughput services. The company’s team of industry experts and scientists has pioneered several firsts in satellite terminal design resulting in a line of terminals that are customizable to meet the performance, cost and power requirements of countless applications – from the most complex government defense systems and mobile backhaul solutions capable of extending 5G, to next-gen connected experiences aboard commercial airliners, cruise ships, offshore rigs, and even small fishing boats at sea. Isotropic Systems’ Series A funding was led by Boeing to advance space-based connectivity. Further information is available at www.isotropicsystems.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200923006010/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
